Affiliations 

  • 1 Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. wlng@ummc.edu.my
  • 2 Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
  • 3 Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
  • 4 Tanglin Health Clinic, Ministry of Health Malaysia, Kuala Lumpur, Malaysia
  • 5 Taman Ehsan Health Clinic, Ministry of Health Malaysia, Selangor, Malaysia
  • 6 Division of Biomedical Science, School of Pharmacy, Faculty of Science and Engineering, University of Nottingham Malaysia, Selangor, Malaysia
  • 7 Division of Dermatology, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
  • 8 Division of Primary Care, School of Medicine, University of Nottingham, NG7 2RD, Nottingham, UK
  • 9 Division of Dermatology, Department of Medicine, Hospital Tengku Ampuan Rahimah, Ministry of Health Malaysia, Selangor, Malaysia
  • 10 Division of Dermatology, Department of Medicine, Hospital Serdang, Ministry of Health Malaysia, Selangor, Malaysia
J Community Genet, 2024 Nov 25.
PMID: 39586937 DOI: 10.1007/s12687-024-00753-4

Abstract

HLA-B*58:01 allele is associated with allopurinol-induced severe cutaneous reaction (SCAR). Malaysia has a multiethnic population with limited data on the prevalence of HLA-B*58:01 among patients with gout treated in primary care settings. This cross-sectional study aimed to determine the prevalence of HLA-B*5801 in patients with gout from the Malay, Chinese and Indian ethnicities attending primary clinics in Malaysia.We collected blood samples from patients with gout attending three primary care clinics in Klang Valley, Malaysia, using convenience sampling. Genomic DNA samples were subjected to typing of HLA-B*5801 by a multiplex probe-based assay in a real-time PCR system, validated by PCR-resequencing approach.547 patients (194 Malay, 266 Chinese and 87 Indian) were recruited. The overall prevalence of HLA-B*58:01 was 16.8% (Chinese 21.8%, Indian 12.6% and Malay 11.9%). None of our 61 HLA-B*58:01 carriers who ever used allopurinol developed SCAR.The overall prevalence of HLA-B*58:01 allele in our patients with gout was high, particularly among the Chinese ethnicity (21.8%). None of our HLA-B*58:01 positive patients treated with allopurinol reported allopurinol-induced SCAR. A more accurate predictive model for allopurinol-induced SCAR is needed.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.